Abstract: Provided herein is a compound of the following structural formula: or a pharmaceutically acceptable salt thereof, wherein values for the variables are as described herein. Also provided herein are compositions comprising a compound of structural formula (I), or a pharmaceutically acceptable salt thereof, and methods of treating a disease, disorder or condition associated with serine hydroxymethyl transferase (SHMT) activity, e.g., cancer, an autoimmune disorder, fibrosis and/or a fibrotic disease, in a subject in need thereof with a compound of structural formula (I), or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are compounds having the following structural formula, wherein values for the variables are as described herein. Also provided are pharmaceutical compositions of the compounds, as well as methods of using the compounds to inhibit the oxidative pentose phosphate pathway, e.g, to treat cancer, malaria, an autoimmune disease, an inflammatory condition or asthma.

Abstract: A novel class of compounds according to Formula I, II, or III, wherein W1-W4, Z1-Z4, Z1-Z5, X, Y, n, and R1-R8 are as defined in the claims and description of embodiments that bind to fatty acid binding protein FABP4 and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5.

Abstract: In one aspect, compounds and associated pharmaceutical compositions are described herein for the treatment of various bacterial infections and/or other diseases. In some embodiments, for example, compounds of Formula (I) and/or salts thereof are described herein.

Abstract: The disclosure provides compounds. In certain embodiments, compounds of the disclosure are capable of inhibiting a mammalian SHMT, such as human SMHT1 and/or SHMT2. Compounds of the disclosure have numerous uses.

Abstract: A method for treating a viral disease in a subject comprising administering to said subject a therapeutically effective dose of one or more compounds that bind to fatty acid binding protein FABP4, with compounds described in the specification some having the general formula, Formula I-Formula XII, where W1-W4, Z1-Z4, Z1-Z5, X, Y, n, and R1-R8 are as defined in the claims and description of embodiments. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5.

Abstract: A method for treating a viral disease in a subject comprising administering to said subject a therapeutically effective dose of one or more compounds that bind to fatty acid binding protein FABP4, with compounds described in the specification some having the general formula, Formula I-Formula XII, where Wi - W4, Z1-Z4, Z1 - Z5, X, Y, n, and R1 - R8 are as defined in the claims and description of embodiments. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5.

Abstract: In one aspect, compounds and associated pharmaceutical compositions are described herein for the treatment of cancer. In some embodiments, for example, a pharmaceutical composition comprises a compound of Formula (I) in an amount sufficient to exhibit anti cancer activity.

Abstract: A class of compounds that bind to FABP4 and inhibit viral replication in cells, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with an additional therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of viral diseases.

Abstract: A class of compounds that bind to fatty acid binding protein (FABP4) and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4.

Abstract: Various disclosed embodiments include a switching module for a charger includes a support member, a first busbar coupled to the support member, the first busbar being configured to conduct electrical current, and a second busbar coupled to the support member, the second busbar being configured to conduct electrical current. The switching module also includes a first switch coupled to the first busbar and configured to move a first contactor. The switching module further includes a second switch coupled to the second busbar and configured to move a second contactor. The switching module also includes a third switch coupled to the first busbar and configured to move a third contactor. Further, the switching module includes a fourth switch coupled to the second busbar and configured to move a fourth contactor, the third and fourth switches being configured to electrically connect and disconnect the first and second busbar with at least a second power dispenser.

Abstract: Provided herein are methods involving a compound of the following structural formula: (I) or a pharmaceutically acceptable salt thereof, wherein values for the variables are as described herein. For example, methods for inhibiting replication of a virus, treating a viral infection, inhibiting heat shock protein 90 and treating a heat shock protein 90-mediated disease or condition using a compound of Structural Formula I are provided.

Abstract: A class of compounds that bind to FABP4 and inhibit viral replication in cells, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with an additional therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of viral diseases.

Abstract: A novel class of compounds according to Formula I, II, or III, wherein W1-W4, Z1-Z4, Z1-Z5, X, Y, n, and R1-R8 are as defined in the claims and description of embodiments that bind to fatty acid binding protein FABP4 and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5.

Abstract: In one aspect, methods of treating bacterial infections are described herein employing compounds having more than one target for antibacterial activity. Additionally, pharmaceutical compositions comprising such compounds are also described.

Abstract: In one aspect, methods of treating bacterial infections are described herein employing compounds having more than one target for antibacterial activity. Additionally pharmaceutical compositions comprising such compounds are also described.

Abstract: The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmune disorders.

Abstract: The disclosure provides compounds. In certain embodiments, compounds of the disclosure are capable of inhibiting a mammalian SHMT, such as human SMHT1 and/or SHMT2. Compounds of the disclosure have numerous uses.

Abstract: The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmue disorders.

Abstract: The present invention relates to a method for the treatment of cancer or an autoimmune disorder, comprising the administration of a serine hydroxymethyltransferase (SHMT) inhibitor, and in particular the administration of pyrazolopyran compounds of Formula (VI) as presently described, wherein the compounds are capable of inhibiting a mammalian SHMT, such as human SHMT1 and/or SHMT2. The treatment method further comprises the optional administration of an additional agent as a rescue therapy to reduce toxicity, wherein said agent may be chosen from formate, a formate salt, folinic acid, formate ester, or leucovorin.